Clinical pathway
Male Hypogonadism
The EAU 2026 male hypogonadism pathway — symptom-triggered diagnosis on a confirmed low morning fasting total testosterone, LH and FSH to separate primary from secondary hypogonadism, the pivotal fertility fork that decides between testosterone therapy and gonadotropins, testosterone preparations and their contraindications, and haematocrit, PSA and cardiovascular safety monitoring. Switch between the visual Pathway map and the phase-by-phase Explorer.
LegendKey state / milestoneDecisionLink to phaseStrong recommendationWeak / conditionalNo formal recommendation
Loading pathway…
Study reference — verify against current EAU guidelines before clinical use. Dashed amber = weak recommendation; dashed taupe = no formal recommendation.